Investor
Cardiac and lung-disease platform Eko Health secured $41 million in Series D funding.
The publicly traded company, which announced it was seeking strategic alternatives for its business last month, will go private thanks to the merger.
The company will use the funds to expand its cloud-based automation platform for providers and pharmaceutical companies.
It is now set to take on the international markets three years after its inception.
This is the latest in its string of acquisitions to expand its digital health portfolio.
The South Korean company now plans to expand the application of its AI to diagnose other medical conditions, including heart and neurological disorders.
The continuous glucose monitoring biosensor platform will use the funds to scale its manufacturing, move toward regulatory approval and perform more clinical trials.
The company will use the funds to enter into strategic relationships with life sciences organizations focusing on oncology and specialty care.
The company offers adults and children virtual care sessions with therapists, homework and educational content.
Sonio will remain an independent company following the acquisition.